ORBIMED ADVISORS LLC 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 6:23 pm Sale | 2025-12-31 | 13G | CYTOMX THERAPEUTICS INC CTMX | ORBIMED ADVISORS LLC | 3,525,650 2.100% | -4,935,850 (-58.33%) | Filing |
| 2025-08-14 6:07 pm Purchase | 2025-06-30 | 13G | CYTOMX THERAPEUTICS INC CTMX | ORBIMED ADVISORS LLC | 8,461,500 5.400% | 8,461,500 (New Position) | Filing |